The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium, and ...